Received Feb 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 92NK2 | — |
administration of an incomplete Engerix-B dose to an adult patient; an unknown volume of the vaccine dripped over the patient´s arm; an unknown volume of the vaccine dripped over the patient´s arm; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete dose administered in a 33-year-old female patient who received HBV (Engerix B) (batch number 92NK2, expiry date 29-SEP-2026) for prophylaxis. On 26-JAN-2025, the patient received Engerix B. On 26-JAN-2025, an unknown time after receiving Engerix B, the patient experienced incomplete dose administered (Verbatim: administration of an incomplete Engerix-B dose to an adult patient), exposure via skin contact (Verbatim: an unknown volume of the vaccine dripped over the patient´s arm) and inadvertent exposure to vaccine (Verbatim: an unknown volume of the vaccine dripped over the patient´s arm). The outcome of the incomplete dose administered, exposure via skin contact and inadvertent exposure to vaccine were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 27-JAN-2025 A pharmacist called to report the administration of an incomplete Engerix-B dose to a patient, which led to an incomplete dose administration. The pharmacist mentioned that during the administration an unknown volume of the vaccine dripped over the patient's arm, which led to an inadvertent exposure to vaccine and exposure via skin contact. The reporter asked if patient should be revaccinated.